

Lack of Congestion Not Predictive in Acute HF

BY BRUCE JANCIN

FROM THE ANNUAL CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY

STOCKHOLM – The absence of signs and symptoms of congestion at discharge in patients hospitalized for acute decompensated heart failure does not predict a favorable prognosis, contrary to the conventional wisdom.

A new secondary analysis of the international EVEREST trial provides an important lesson in the everyday management of acute heart failure: “The fact that a patient improves in-hospital with diuretics and other medications is not sufficient. It’s not ‘mission accomplished,’” Dr. Mihai Gheorghiade said at the congress.

“There is a dissociation between signs and symptoms of congestion at discharge and outcomes. In spite of having a very low congestion score, the event

group, all-cause mortality was 26%, with a 40% rate of rehospitalization for heart failure during follow-up.

group, all-cause mortality was 26%, with a 40% rate of rehospitalization for heart failure during follow-up.

rate in EVEREST during 10 months of follow-up was astronomical,” said Dr. Gheorghiade, professor of medicine and surgery and associate chief of cardiology at Northwestern University, Chicago.



BRUCE JANCIN/ELSEVIER GLOBAL MEDICAL NEWS

Dr. Mihai Gheorghiade: The event rate in EVEREST was “astronomical.”

rate in EVEREST during 10 months of follow-up was astronomical,” said Dr. Gheorghiade, professor of medicine and surgery and associate chief of cardiology at Northwestern University, Chicago.

EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan) was a double-blind study that randomized 4,133 patients with worsening heart failure and a left ventricular ejection fraction of 40% or less to the oral vasopressin V2 receptor blocker tolvaptan or placebo within 48 hours of hospitalization.

Standard background therapy in both study arms included diuretics, ACE inhibitor or angiotensin II receptor blocker therapy, a beta-blocker, and an aldosterone antagonist. In the previously reported primary results, tolvaptan proved to have no benefit over placebo during a mean follow-up of 9.9 months (JAMA 2007;297:1319-31).

Dr. Gheorghiade presented a secondary analysis focusing on the 2,061 patients in the placebo arm. At randomization, following initial treatment with diuretics, these patients had a mean congestion score of 4 points based on their degree of jugular vein distention, rales, and peripheral edema.

At discharge, patients had lost a mean 2.8 kg of body weight, and 72% had a

group, all-cause mortality was 26%, with a 40% rate of rehospitalization for heart failure during follow-up.

“We’re dealing with a disorder that has an event rate as high as 50%. There is no other medical condition for which patients are hospitalized and are improving with therapy that has a comparable event rate,” the cardiologist observed.

The new EVEREST analysis contains an important message for clinical trial-

ists: Using signs and symptoms of congestion as a key target for treatment during hospitalization as well as the standard end point in acute heart failure studies, as has been common until now, is a recipe for a negative trial result.

“It’s very difficult to beat placebo, because placebo plus standard therapy has a tremendous effect on congestion,” Dr. Gheorghiade said. “Looking for new therapies that improve signs and symp-

INDICATIONS AND USAGE

Effient is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows: [1] patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI); [2] patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI.



toms of congestion in the whole population is a waste of time unless you're dealing with special populations who don't respond to standard therapies, such as patients with low blood pressure."

Better surrogate markers than congestion are needed to guide therapy. One possibility is B-type natriuretic peptide (BNP). The mean BNP at admission in the placebo arm of EVEREST was 1,375 pg/mL. At discharge it was still markedly elevated at 948 pg/mL.

"The lesson here is that by treating the signs and symptoms of congestion, you can make patients feel much better, but

even though they are now able to walk up a flight of stairs, inside, in terms of renal function and BNP, they are still very sick," he said.

Until better treatments for acute heart failure are found, the best thing physicians can do for patients is try to identify specific targets amenable to current therapies, such as renal dysfunction or myocardial ischemia, Dr. Gheorghiade said.

The EVEREST trial was sponsored by Otsuka. Dr. Gheorghiade has received research grants and/or served as a consultant to Otsuka and numerous other pharmaceutical companies. ■

Medical
News Net

Want Daily
Medical News
and Commentary?

Follow us on 
Twitter.com/MedicalNewsNet

Effient® plus aspirin (ASA) provided

STRONGER PROTECTION

vs Plavix® (clopidogrel bisulfate) plus ASA against thrombotic cardiovascular (CV) events (including stent thrombosis)

- In the overall UA/NSTEMI population, event rates* for Effient plus ASA and Plavix plus ASA were 9.3% and 11.2%, respectively (1.9% ARR†; P=0.002). In the overall STEMI population, event rates for Effient plus ASA and Plavix plus ASA were 9.8% and 12.2%, respectively (2.4% ARR; P=0.019)¹²
- In the overall study, the benefit in each population was primarily driven by a significant reduction in nonfatal myocardial infarctions (MIs), with no significant differences in CV death or nonfatal stroke¹
– Approximately 40% of MIs occurred periprocedurally and were detected solely by changes in CK-MB
- 52% RRR‡ in stent thrombosis in the all-ACS population with Effient plus ASA vs Plavix plus ASA (1.1% vs 2.2%; 1.1% ARR; P<0.0001)³
- In TRITON-TIMI 38, the loading dose of Plavix was delayed relative to the placebo-controlled trials that supported its approval for ACS

For more information, please visit EffientHCP.com or Effientconferences.com.

SELECTED SAFETY, INCLUDING SIGNIFICANT BLEEDING RISK

Effient can cause significant, sometimes fatal, bleeding. In TRITON-TIMI 38, overall rates of non-CABG TIMI major or minor bleeding were significantly higher with Effient plus ASA (4.5%) compared with Plavix plus ASA (3.4%). In patients who underwent CABG (n=437), the rates of CABG-related TIMI major or minor bleeding were 14.1% with Effient plus ASA and 4.5% with Plavix plus ASA.

IMPORTANT SAFETY INFORMATION

WARNING: BLEEDING RISK

Effient® (prasugrel) can cause significant, sometimes fatal, bleeding. Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack or stroke. In patients ≥75 years of age, Effient is generally not recommended, because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior MI) where its effect appears to be greater and its use may be considered. Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery. Additional risk factors for bleeding include: body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding (eg, warfarin, heparin, fibrinolytic therapy, chronic use of nonsteroidal anti-inflammatory drugs [NSAIDs]). Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of Effient. If possible, manage bleeding without discontinuing Effient. Discontinuing Effient, particularly in the first few weeks after acute coronary syndrome, increases the risk of subsequent cardiovascular events.

- Effient is contraindicated in patients with active pathological bleeding, such as from a peptic ulcer or intracranial hemorrhage (ICH), or a history of transient ischemic attack (TIA) or stroke
- Patients who experience a stroke or TIA while on Effient generally should have therapy discontinued. Effient should also be discontinued for active bleeding and elective surgery
- Premature discontinuation of Effient increases risk of stent thrombosis, myocardial infarction (MI), and death
- Thrombotic thrombocytopenic purpura (TTP), a rare but serious condition that can be fatal, has been reported with the use of other thienopyridines, sometimes after a brief exposure (<2 weeks), and requires urgent treatment, including plasmapheresis

Please see Brief Summary of Prescribing Information on adjacent pages.

*As measured by reduction in the primary composite endpoint of CV death, nonfatal MI, or nonfatal stroke.

†Absolute risk reduction.

‡Relative risk reduction.

 **Effient**
(prasugrel) tablets